American Century Companies Inc. Acquires 1,374 Shares of Masimo Co. (NASDAQ:MASI)

American Century Companies Inc. raised its holdings in shares of Masimo Co. (NASDAQ:MASI) by 12.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 12,659 shares of the medical equipment provider’s stock after acquiring an additional 1,374 shares during the period. American Century Companies Inc.’s holdings in Masimo were worth $2,093,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its position in shares of Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares during the last quarter. Blue Trust Inc. raised its position in Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Masimo by 0.8% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after purchasing an additional 82 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after purchasing an additional 83 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company’s stock.

Masimo Price Performance

Shares of Masimo stock opened at $145.06 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The business’s 50 day simple moving average is $171.98 and its two-hundred day simple moving average is $163.67. The stock has a market capitalization of $7.84 billion, a P/E ratio of 100.04 and a beta of 1.28.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

MASI has been the topic of a number of research reports. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company lifted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler boosted their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.